ce as individuals with genital herpes have an increased risk (5 to 7 times greater risk) of contracting the AIDS virus.
A Phase I clinical trial involving the new drug is expected to be launched soon. If the results are satisfactory, the drug would be approved for use in the US, Australia and Europe by the end of 2008.